International multicenter examination of MOG antibody assays

International multicenter examination of MOG antibody assays

<p><strong>Objective</strong> To compare the reproducibility of 11 antibody assays for immunoglobulin (Ig) G and IgM myelin oligodendrocyte glycoprotein antibodies (MOG-IgG and MOG-IgM) from 5 international centers.</p> <p><strong>Methods</strong> The follo...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Reindl, M, Schanda, K, Woodhall, M, Ramberger, M, Leite, MI, Palace, J, Irani, SR, Waters, P
Formato:	Journal article
Idioma:	English
Publicado em:	Lippincott, Williams and Wilkins 2020

Registros relacionados

A multicenter comparison of MOG-IgG cell-based assays
por: Waters, P, et al.
Publicado em: (2019)

An international multicentre validation experiment for MOG antibodies
por: Reindl, M, et al.
Publicado em: (2018)

Frequency of MOG-IgG in cerebrospinal fluid versus serum
por: Pace, S, et al.
Publicado em: (2021)

MOG cell-based assay detects non-MS patients with inflammatory neurologic disease
por: Waters, P, et al.
Publicado em: (2015)

Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS
por: Waters, P, et al.
Publicado em: (2015)

Distinguishing the brain MRI features of MS, AQP4-and MOG-antibody disease.
por: Jurynczyk, M, et al.
Publicado em: (2016)

RELAPSING AQP4 ANTIBODY NEGATIVE NMO WITH MOG ANTIBODIES
por: Elsone, L, et al.
Publicado em: (2014)

Recurrent optic neuritis associated with MOG antibody seropositivity
por: Chang, T, et al.
Publicado em: (2017)

MOG-IgA as a potential marker of germinal center activity
por: Handel, AE, et al.
Publicado em: (2024)

A 41-year-old woman with acute weakness and encephalopathy associated with MOG antibodies.
por: Morris, K, et al.
Publicado em: (2015)

Disease course and disability outcomes in MOG-antibody disease in the UK
por: Jurynczyk, M, et al.
Publicado em: (2017)

No strong HLA association with MOG antibody disease in the UK population
por: Grant-Peters, M, et al.
Publicado em: (2021)

Clinical presentation and prognosis in MOG-antibody disease: a UK study
por: Jurynczyk, M, et al.
Publicado em: (2017)

Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease.
por: Jurynczyk, M, et al.
Publicado em: (2017)

Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease
por: Jurynczyk, M, et al.
Publicado em: (2017)

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
por: Waters, P, et al.
Publicado em: (2016)

MOG encephalomyelitis: international recommendations on diagnosis and antibody testing
por: Jarius, S, et al.
Publicado em: (2018)

MOG-IgG1 antibodies in children
por: Waters, P, et al.
Publicado em: (2018)

Factors associated with fatigue in CNS inflammatory diseases with AQP4 and MOG antibodies
por: Yeo, T, et al.
Publicado em: (2020)

Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease
por: Juryńczyk, M, et al.
Publicado em: (2016)

Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients
por: Whittam, DH, et al.
Publicado em: (2020)

We need to talk about MOG
por: Waters, P, et al.
Publicado em: (2020)

Refining cell-based assay to detect MOG-IgG in patients with central nervous system inflammatory diseases
por: Kim, Y, et al.
Publicado em: (2020)

Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies.
por: Kaneko, K, et al.
Publicado em: (2016)

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
por: Sato, D, et al.
Publicado em: (2014)

Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.
por: Waters, P, et al.
Publicado em: (2012)

Prospective clinical and MRI characterization of children with serum anti-MOG antibodies meeting the multiple sclerosis diagnostic criteria
por: Fadda, G, et al.
Publicado em: (2018)

Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders
por: Rinaldi, S, et al.
Publicado em: (2020)

Peripheral nervous system involvement in MOG antibody-associated demyelination
por: Ramanathan, S, et al.
Publicado em: (2019)

Anti-MOG Antibodies in Japanese Patients with Neuromyelitis Optica Spectrum Disorders
por: Sato, D, et al.
Publicado em: (2014)

Anti-MOG Antibody Seropositive Patient Successfully Treated with Intermittent Rituximab Infusion
por: Kim, W, et al.
Publicado em: (2014)

Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis
por: Hyun, J, et al.
Publicado em: (2018)

Teratoma-derived glycine receptor antibodies in progressive encephalomyelitis with rigidity and myoclonus
por: Sun, B, et al.
Publicado em: (2019)

Humoral signatures of MOG-antibody-associated disease track with age and disease activity
por: Spatola, Marianna, et al.
Publicado em: (2023)

AQUAPORIN-4 M 23 ISOFORM PROVIDES A MORE SENSITIVE ASSAY FOR AQUAPORIN-4 ANTIBODIES
por: Waters, P, et al.
Publicado em: (2010)

Utility of live cell-based assays for autoimmune neurology diagnostics
por: Woodhall, M, et al.
Publicado em: (2022)

MOG-IGG IN NMO AND NMO-LIKE DISORDERS
por: Luppe, S, et al.
Publicado em: (2014)

Aquaporin-4 Antibody Isoform Binding Specificity Does Not Explain Clinical Variations in Neuromyelitis Optica
por: Kitley, J, et al.
Publicado em: (2013)

NMDA receptor antibody encephalitis presenting as Transient Epileptic Amnesia
por: Savage, SA, et al.
Publicado em: (2019)

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
por: Kezuka, T, et al.
Publicado em: (2014)